Chris Doughty - Prometheus Biosciences Chief Officer

Insider

Chris Doughty is Chief Officer of Prometheus Biosciences
Phone858 684 1300
Webhttps://www.prometheusbiosciences.com

Prometheus Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Prometheus Biosciences currently holds 14.76 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Prometheus Biosciences has a current ratio of 13.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Prometheus Biosciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Dean MDPliant Therapeutics
N/A
Isabel AznarezStoke Therapeutics
52
Paul MDMadrigal Pharmaceuticals
81
FACC MDStoke Therapeutics
61
Tracey EsqBlueprint Medicines Corp
57
James MBAAmylyx Pharmaceuticals
58
Margaret MBAAmylyx Pharmaceuticals
59
Johannes HullPliant Therapeutics
50
Ryan Martins89bio Inc
47
Tom HolmesAmylyx Pharmaceuticals
N/A
Dawn KalmarStoke Therapeutics
47
Gloria LinKrystal Biotech
N/A
Melissa Abel89bio Inc
N/A
Rohan Palekar89bio Inc
59
Rik DerynckPliant Therapeutics
N/A
Nur NicholsonApellis Pharmaceuticals
54
Charles IIDay One Biopharmaceuticals
47
PharmD ChiodinDay One Biopharmaceuticals
N/A
Rami ElghandourArcellx
46
Quoc LeNguyen89bio Inc
57
Vivek RamaswamyRoivant Sciences
39
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. Prometheus Biosciences (RXDX) is traded on NASDAQ Exchange in USA and employs 97 people.

Management Performance

Prometheus Biosciences Leadership Team

Elected by the shareholders, the Prometheus Biosciences' board of directors comprises two types of representatives: Prometheus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prometheus. The board's role is to monitor Prometheus Biosciences' management team and ensure that shareholders' interests are well served. Prometheus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prometheus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Allison MD, Chief Officer
Noel Kurdi, VP Communications
Timothy Esq, G Sec
Chris Doughty, Chief Officer
Mark McKenna, CEO Pres
Nori Ebersole, Chief Officer
Olivier Laurent, Chief RD
MBA MBA, Chief Officer
Mark Stenhouse, Chief Officer

Prometheus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prometheus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA